Silence Therapeutics Plc - American Depository Share (NQ:SLN)

10.64 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >

Silence Therapeutics Announces Leadership Changes

December 15, 2025

From Silence Therapeutics plc

Via Business Wire

Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake ↗

December 10, 2025

Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.

Via The Motley Fool

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

November 12, 2025

From Silence Therapeutics plc

Via Business Wire

Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗

March 04, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗

February 03, 2025

Via Benzinga

The Analyst Landscape: 6 Takes On Silence Therapeutics ↗

December 10, 2024

Via Benzinga

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 06, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

October 23, 2025

From Silence Therapeutics plc

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

Silence Therapeutics to Participate in September Investor Conferences

September 02, 2025

From Silence Therapeutics plc

Via Business Wire

Silence (SLN) Q2 Revenue Drops 71% ↗

August 07, 2025

Via The Motley Fool

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 07, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025

From Silence Therapeutics plc

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 13, 2025

Via Benzinga

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 08, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 06, 2025

From Silence Therapeutics plc

Via Business Wire

These stocks are moving in today's pre-market session ↗

April 01, 2025

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 05, 2025

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025

From Silence Therapeutics plc

Via Business Wire

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 ↗

February 15, 2025

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.

Via Talk Markets

Topics Stocks / Equities

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

February 13, 2025

From Silence Therapeutics plc

Via Business Wire

This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 11, 2025

Via Benzinga

Top 3 Health Care Stocks That May Explode In Q4 ↗

December 18, 2024

Via Benzinga

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

December 09, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst ↗

November 19, 2024

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.

Via Benzinga

Top 3 Health Care Stocks You'll Regret Missing In Q4 ↗

November 19, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.